Dallas, TX (PRWEB) December 07, 2013
The report titled "Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)" provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2013-18). Further, key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report.
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that principally attacks synovial joints. It is one of the most common autoimmune diseases affecting people of all ages and races. RA affects the lining of joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. It also leads to stiffness, and redness in the joints. The main factor causing rheumatoid arthritis remains unknown. However, according to studies around the world some of the genetic and environmental factors are found to be more probable causers. Complete report available at http://www.marketreportsonline.com/295942.html.
Company Coverage: Abbvie Inc., Amgen Inc., Johnson & Johnson, Roche Holdings AG
Treatment of Rheumatoid Arthritis involves frequent drugs administration as RA is a progressive and incurable disease. Drugs used for treatment of RA are classified as first line agents- consisting of non-steroidal anti-inflammatory drugs (NSAIDs) and steroids such as glucocorticoids and second line agents- consisting of disease modifying anti-rheumatic drugs such as chloroquine, gold salts, penicillamine, cyclosporine, and several biological agents like TNF- and interleukin-1 inhibitors.
Global rheumatoid arthritis market is driven by increase in incidences of RA patients, global ageing population and increasing healthcare expenditure by government of various nations. Factors which are affecting pharmaceutical companies are pricing pressure, patent expiries of RA drugs, high costs of treatments involved and escalating R&D costs. The market is characterized by use of auto-injectors by patients for RA treatment, increase in RA cases in women and FDA approvals for RA drugs. Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=295942.
Few Points from Table of Contents are listed below:
1. Executive Summary
2. Rheumatoid Arthritis: An Introduction
2.1 Rheumatoid Arthritis: Causes
2.2 Rheumatoid Arthritis: Symptoms & Diagnosis
2.2.1 Rheumatoid Arthritis: Symptoms
2.2.2 Rheumatoid Arthritis: Diagnosis
3. Rheumatoid Arthritis Treatment
3.1 Clinical Evolution of Rheumatoid Arthritis Treatment
3.2 Rheumatoid Arthritis: Drugs Treatment
3.2.1 First line agents
3.2.2 Second line agents
4. Global Rheumatoid Arthritis Market Analysis
4.1 Global Rheumatoid Arthritis Treatment Market: Size & Growth (Actual & Forecast)
4.2 Global Rheumatoid Arthritis Treatment Market Analysis
4.2.1 Global Biologics Drugs Market Size (Actual & Forecast)
4.2.2 Global Rheumatoid Arthritis Biologics Drugs Market Share (Actual & Forecast)
4.2.3 Global TNF- target Antibody Market Size (Actual & Forecast)
5. Global Rheumatoid Arthritis Drug Market Analysis
5.1 Global TNF- target Drugs Market
5.1.1 Global TNF- target Market Size by Drugs (Actual & Forecast)
5.1.2 TNF- target Market Share by Drugs (Actual & Forecast)
5.2 Rheumatoid Arthritis Drugs Market: Regional Analysis
5.2.1 Rheumatoid Arthritis Drugs Market Size in the U.S. (2012)
5.2.2 TNF? Blockers Drugs Market Size in the U.S. (2012)
5.2.3 Rheumatoid Arthritis Drugs Market Size in Korea
6. Global Rheumatoid Arthritis Market: Growth Drivers & Challenges
6.1 Growth Drivers
6.1.1 Increase in Incidence of Patients with Rheumatoid Arthritis
6.1.2 Global Aging Population
6.1.3 Global Healthcare Expenditure
6.2.1 Pricing pressure
6.2.2 Patent Expiries
6.2.3 High Cost of Treatment
6.2.4 High R&D Costs
7. Global Rheumatoid Arthritis Market Trends
7.1 Auto-Injectors for Rheumatoid Arthritis Treatment
7.2 Increase in Rheumatoid Arthritis in Women
7.3 Licensing Deals
7.4 FDA Approvals of Rheumatoid Arthritis Drugs
7.5 Rheumatoid Arthritis Drugs in R&D Pipeline
8. Global Rheumatoid Arthritis Market: Competitive Landscape
9. Company Analysis: Global Rheumatoid Arthritis Market
9.1 AbbVie Inc. (Abbott Laboratories)
9.2 Amgen Inc.
9.3 Johnson & Johnson Services Inc.
9.4 Roche Holdings AG
Explore more reports on Pharmaceuticals markets at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.
Osteoarthritis Partnering 2007-2013 (http://www.marketreportsonline.com/223655.html) at: The report provides an analysis of osteoarthritis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors asthma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Global Testosterone Therapy Market: Trends and Opportunities 2013-2018 (http://www.marketreportsonline.com/295936.html) at: The report titled "Global Testosterone Therapy Market": Trends & Opportunities (2013-2018)" provides an in-depth analysis of the global Testosterone Therapy market with detailed analysis of symptoms, diagnosis and treatment of testosterone deficiency.
MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication.